Evaxion Biotech (EVAX) has released an update.
Evaxion Biotech’s AI-designed personalized cancer vaccine, EVX-01, has shown a 67% objective response rate in a Phase 1 trial for metastatic melanoma, with no serious adverse events reported. The vaccine, tailored to individual patients’ tumor profiles, has progressed to a Phase 2 study, showcasing the potential of the company’s AI-Immunology platform in developing novel cancer therapies.
For further insights into EVAX stock, check out TipRanks’ Stock Analysis page.
